A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
Phase 3
125
about 2.4 years
12–17
15 sites in CA, CT, GA +9
About this study
Researchers are testing a treatment called orforglipron versus a placebo in adolescents with obesity or overweight and related health problems. The trial will last about 18 months.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Orforglipron
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Percent Change from Baseline in Body Mass Index (BMI)
Secondary: Change from Baseline in BMI, Change from Baseline in Body Weight, Change from Baseline in Body Weight Percentile, Change from Baseline in Diastolic Blood Pressure, Change from Baseline in Fasting Glucose, Change from Baseline in Systolic Blood Pressure, Change from Baseline in Waist Circumference, Change in Impact of Weight on Quality of Life (IWQOL)-Kids Total and Domain Scores
Endocrinology